Scott Weir, Pharm.D., Ph.D.
Director, Institute for Advancing Medical Innovation, University of Kansas
Associate Director – Translational Research, University of Kansas Cancer Center
Kelly Family Endowed IAMI Professor in Cancer Drug Discovery and Development
Pharm.D., University of Nebraska College of Pharmacy, 1980
Ph.D., University of Nebraska Medical Center, 1986
Dr. Weir's research interests include clinical pharmacology, pharmacokinetics/pharmacodynamics of anti-cancer agents, lead optimization and early drug development strategies to achieve "fast into humans" translation, public-private partnerships in drug discovery and development, pediatric drug product development, biopharmaceutics characterization of drug product performance, product development-focused translational research and patient engagement in translational research.
KU Medical Center Roles:
Since joining the University of Kansas 13 years ago, Weir has established pharmaceutical industry best practices, recruited industry veterans, formed and reorganized supported cores and centers, and established strategic partnerships with industry, academia, government and disease philanthropy organizations, all focused on supporting the discovery, delivery and clinical evaluation of new drug therapies for the treatment and prevention of human disease. Weir has two roles within the University of Kansas. Weir directs the Institute for Advancing Medical Innovation (IAMI). IAMI is an academic proof of concept center that translates peer review-funded basic research into medical innovations, and using an industry approach, executes product development-focused translational research to de-risk the technologies with the intent of partnering those with promise. To date, IAMI has invested over $8.3M in 53 projects, ten of which have resulted in royalty-bearing licenses. IAMI partnered with Silvergate Pharmaceuticals and Children's Mercy Kansas City to successfully develop EpanedTM, a drug product prescribed for the treatment of cardiovascular disorders in children. This product was approved by FDA and commercially launched in 2013. IAMI's therapeutic areas of focus are cancer and rare diseases afflicting children, adolescents, and adults. IAMI partners with faculty to develop drugs, diagnostics and medical device technologies and then leads efforts to partner promising medical innovations with the private sector. In 2015, IAMI established a preferred partnership with BioNovus Innovations LLC to co-develop the most promising drug, diagnostic and medical device products created and de-risked by KU product development teams. The first co-development project supported by this unique and innovative partnership, Ciclopirox Prodrug, is currently being evaluated in a multi-center First-in-Human Phase 1 trial in patients with advanced solid tumor cancers.
In his role as associate director of translational research for the University of Kansas Cancer Center (KUCC), Weir is charged with enabling, facilitating and managing intra-programmatic and inter-programmatic translational research collaborations across the four cancer research programs. Weir also serves as a point person for establishing collaborations with other NCI Cancer Centers. Over the past eight years, KUCC and IAMI have collaborated with industry, academia, government and disease philanthropy organizations to advance 19 new cancer treatments to patients. Along with Dr. John A. Taylor III, Weir co-leads the experimental therapeutics research program within KUCC. He also co-chairs the drug discovery and development (D3SC) and investigator-initiated (TTSC) steering committees that serve as translational research catalysts for advancing promising laboratory and bedside discoveries from the bench-to-the-bedside as well as from the bedside to the bench and back again.
From 2012-2017, Dr. Weir served on the National Center for Advancing Translational Science (NCATS) Advisory Council and Cures Acceleration Network Board. In these roles, he advised NCATS Director Christopher Austin on NIH translational research initiatives, policies, and programs. In 2013-2014, Weir co-chaired the NCATS Advisory Council Working Group, a consortium of approximately 62 clinical and translational science centers across the US, including the Kansas City regional CTSA Frontiers: University of Kansas Clinical and Translational Science Institute. Weir also served on the Best Practices for Patient Engagement team of the Clinical Trial Transformation Initiative as well as the Institute of Medicine Working Group on Mapping the Drug Discovery and Development Process. He currently serves on external or scientific advisory boards for the University of Kentucky Center for Clinical and Translational Research, Center for Drug Delivery at Washington University, Myeloproliferative Neoplasm Research Foundation and Family Health International 360, as well as serving on the board of directors for the Leo and Anne Albert Institute for Bladder Cancer Patient Care and Research.
Dr. Weir joined Marion Laboratories, Inc. in 1986 as a clinical pharmacokineticist. From 1988 through 1998, Dr. Weir assumed a series of management positions with increasing responsibility at Marion Laboratories, Inc., Marion Merrell Dow, Inc, Hoechst Marion Roussel, Inc. and Aventis Pharmaceuticals, Inc. Over this same period, Weir was directly involved in the successful registration of over 20 drug products across a wide range of therapeutic areas such as: Cardizem CD®, Cardizem Injectable®, Anzemet Tablets®, Anzemet Injectable®, Pentasa®, Carafate Tablets®, Carafate Suspension®, Priftin®, Rifater®, Ketek®, and the family of Allegra® drug products. Dr. Weir was actively involved in research and development reengineering efforts for these companies in 1992 and 1997. As well, Dr. Weir led the global integration and harmonization activities for drug metabolism and pharmacokinetics during the Hoechst Marion Roussel, Inc. merger. Following sale of the North America drug development center of Hoechst Marion Roussel, Inc. located in Kansas City, Missouri, to Quintiles, Inc. in January, 1999, Dr. Weir managed an early drug development division which included pharmacology, toxicology, drug metabolism and pharmacokinetics, bioanalytical, and clinical pharmacology services. Dr. Weir continued these responsibilities until his departure in early 2006 to join the University of Kansas Medical Center.